Background: In US men, prostate cancer is the most common noncutaneous cancer and the
second leading cause of cancer death. Screening for prostate cancer is controversial …

Proton therapy may offer potential clinical advantages compared with conventional radiation
therapy for many cancer patients. Due to the large investment costs for building a proton …

Context In the United States, 192 000 men were diagnosed as having prostate cancer in
2009, the majority with low-risk, clinically localized disease. Treatment of these cancers is …

The incidence of prostate cancer varies by> 100-fold in the world, being most common in the
so-called Western world and least common in South-east Asia [1]. During recent years the …

Good risk prostate cancer, defined as a Gleason score of≤ 6, prostate-specific antigen
(PSA)< 10, and T1c–T2a, now constitutes 50% of newly diagnosed prostate cancer. Recent …

PURPOSE: This article reviews the data supporting an approach of active surveillance with
selective delayed intervention for good risk localized prostate cancer. The challenge is to …

Background Few studies investigated long-term overall survival and causes of death among
men and women diagnosed with most commonly occurring cancers. Methods We estimated …

Introduction Prostate specific antigen (PSA) screening results in the detection of prostate
cancer in many men who are not destined to die from the disease. This often results in …

Good risk prostate cancer, defined as patients with a Gleason score of 6 or less, PSA< 10–
15, and T1c–T2a, now constitutes 50% of newly diagnosed prostate cancer. For most of …

OBJECTIVE: This observational cohort study describes the long-term outcome of patients
with clinically localized prostate cancer managed with watchful waiting, the prognostic value …